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Acute coronary syndromesSince its description in 1966, adiponectin, a family member of
adipocytokines, appears to be the most promising one studied to
date with a potential impact on the development of therapeutic
strategies in the ﬁeld of cardiovascular disease [1]. However, the
potential usefulness of different adipocytokines in the ﬁeld of
cardiovascular medicine and their value in our ‘‘every-day’’ clinical
practice are still uncertain.
We read with great interest the article titled ‘‘Time-dependent
changes of plasma adiponectin concentration in relation to
coronary microcirculatory function in patients with acute myo-
cardial infarction (MI) treated by primary percutaneous coronary
intervention’’ by Trifunovic D et al. [2]. They have analyzed plasma
adiponectin kinetics in patients with ST-segment elevation
myocardial infarction (STEMI) without heart failure treated by
primary percutaneous coronary intervention (pPCI) and its
association with coronary ﬂow reserve (CFR). It has been
concluded that low plasma adiponectin concentrations are
strongly associated with impaired coronary microcirculatory
function in patients with their ﬁrst anterior STEMI treated by
pPCI, especially during the early post-pPCI period.
Higher adiponectin concentrations correlate with a lower risk
of ﬁrst MI and chronic coronary heart disease. However, there are
also studies indicating the possibility that adiponectin has
differing prognostic implications depending upon the type of
cardiovascular disease and its severity. Higher adiponectin levels
have been associated with an increased risk of future adverse
cardiovascular events in patients with symptomatic coronary
artery disease or acute coronary syndromes [3]. In other words,
depending on the clinical settings of patients, both higher and
lower levels of adiponectin have been considered as a predictor of
increased risk of future adverse cardiovascular events.
We would like to discuss two aspects of the study by Trifunovic
et al. to understand more clearly the relationship between
adiponectin levels and the clinical course of acute STEMI patients.
Firstly, it could have been more useful if the authors could
quantify the extent of myocardial necrosis with more sensitive
measures, although no correlation was noted between adiponectin
and other markers of myocardial damage, namely troponin (Tn) I and0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightscreatine kinase (CK)-MB. However, TnI and CK-MB levels were
considerably high, although not statistically signiﬁcant, in patients
with CFR < 2. The relatively low number of study subjects could be
responsible for this. On the other hand, infarct size determined by
means of scintigraphy is known to correlate better with 1-year
mortality than any other biomarker [4]. Patients with impaired CFR
had higher Killip class on admission, and larger left ventricles with
lower ejection fractions as compared to patients with preserved CFR,
all of which indicate that a greater extent of myocardium is more
likely to be affected in this patient subset. Observation of higher
admission white blood cell and neutrophil counts and higher high-
sensitivity C-reactive protein levels in patients with CFR < 2 lend
further support to this.
In the present study, left ventricular ejection fraction values and
adiponectin levels were found to be independent predictors of
recovery of CFR. If the myocardial injury and developing scar area
had been quantiﬁed by more sensitive methods, in which direction
would they inﬂuence the independent predictive value of adipo-
nectin levels for recovery of CFR? In other words, the question of
whether the adiponectin levels are merely an indicator or an active
regulator of recovery of CFR has not been clearly answered, as
pointed out partly by the authors of this study. It seems that this is an
interesting subject, which needs to be evaluated in detail.
The second point that we would like to discuss is when and
which cut-off value of adiponectin levels should be used in
predicting cardiovascular events. In the current study, the
adiponectin values obtained at the second day of acute MI
(4.04 mg/mL) best predict the worse outcome regarding recovery
of CFR. However, in another study, an admission adiponectin level
of 3.8 mg/mL has been reported as the best cut-off to predict
major adverse clinical events in males after STEMI, whereas an
adiponectin level of 4.7 mg/mL at day 7 after STEMI has been
found to be the best cut-off in predicting left ventricular
remodeling in another study [5].
In conclusion, adiponectin levels show dynamic changes during
the course of acute coronary syndromes. The question of when and
which cut-off value is the worthiest remains unresolved. Adipo-
nectin levels measured after the beginning of STEMI may be more
valuable in predicting worse cardiovascular outcomes as compared
to the admission adiponectin levels. However, this needs to be
evaluated in large-scale studies, as admission levels of any
biochemical marker would be more useful in the guidance of the
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Author’s reply
We thank Professor Amasyali and Professor Kilic for their
interest in our paper ‘‘Time-dependent changes of plasma
adiponectin concentration in relation to coronary microcirculatory
function in patients with acute myocardial infarction (MI) treated
by primary percutaneous coronary intervention (pPCI)’’ recently
published by the Journal of Cardiology. They discussed two aspects
of our work.
First, we have the impression that the primary end point of our
study, the recovery of coronary microcirculatory function (CMF)
assessed as coronary ﬂow reserve (CFR), is misread as the size of
the infarction. CMF in ST-elevation MI (STEMI) patients after pPCI
is indeed closely related to the quantity of myocardial damage, but
is not its surrogate. Impaired CMF after pPCI is a complex
phenomenon [1] and we focused on analysis of its predictors.
Although we found white blood cell and neutrophil count, bloodglucose and Killip class on admission and peak troponin I as
signiﬁcant univariate predictors of impaired CFR, in multivariate
analysis (i.e. after adjustment for these variables), low adiponectin
concentrations remained an independent predictor of impaired
CFR in three separate models. These data suggest a strong
relationship between low adiponectin concentration and impaired
CMF, independently from other covariables. Since this is not an
interventional study, causal or non-causal connection between
impaired CMF and low plasma adiponectin cannot be presumed.
The second question was the cut-off value of adiponectin
concentration for predicting poor outcome in STEMI and the
optimal sampling time. We conﬁrmed dynamic changes of
adiponectin concentration during the ﬁrst week in STEMI patients.
Adiponectin’s predictive value and its cut-off depend on the
endpoint selection. Comparing ours with the results of other
authors, we believe that minimal adiponectin concentration (i.e.
lower limit) of around 4 mg/ml is important, whenever it is reached
(i.e. on admission or 48 h after pPCI). The lower limit of 4 mg/ml of
adiponectin concentration on the 2nd day after pPCI was found as
the best predictor of impaired CFR in our study. It is close to the
3.8 mg/ml of adiponectin concentration found on admission as best
predictor of major adverse clinical events in males after STEMI
[2]. Shibata et al. [3] found adiponectin 4.7 mg/ml at day 7 after
STEMI as the best cut-off to predict left ventricular remodeling.
These cut-offs should be compared with caution, since they predict
comparable but not identical endpoints.
Large-scale studies are always welcome, although our study
had enough statistical power to test the predeﬁned hypothesis.
In our opinion the major breakthrough would be to test
whether early application of the recombinant adiponectin in
STEMI patents prior to or soon after pPCI would have an impact on
coronary microcirculation and ﬁnal infarct size, since there are
positive data from animal models [4]. To the best of our knowledge,
to date there are no such data.
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